The Technical AnalystExchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
SAB Biotherapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0300
/ 10 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 44.43 mill |
| EPS: | 0.292 |
| P/E: | 0.100 |
| Earnings Date: | Mar 30, 2023 |
| SharesOutstanding: | 1 480.93 mill |
| Avg Daily Volume: | 0 mill |
| RATING 2024-04-10 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0.100 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 0.100 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$6.95 (23 058.50%) $6.92 |
| Date: 2024-04-17 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0154 - 0.0454 ( +/- 49.34%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-07 | Sullivan Eddie Joe | Buy | 1 740 | Common Stock |
| 2023-11-30 | King Michael | Buy | 5 000 | Common Stock |
| 2023-11-29 | Reich Samuel J | Buy | 11 000 | Common Stock |
| 2023-11-24 | Sessa Capital (master), L.p. | Buy | 4 584 571 | Common Stock |
| 2023-11-24 | Sessa Capital (master), L.p. | Buy | 28 380 | Series A-2 Convertible Preferred Stock |
| INSIDER POWER |
|---|
| 67.43 |
| Last 48 transactions |
| Buy: 15 469 696 | Sell: 3 137 380 |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0300 (0.00% ) |
| Volume | 0.0030 mill |
| Avg. Vol. | 0 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SABSW
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SABSW
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.